

SYNTHESIS, SPECTRAL CHARACTERIZATION AND STRUCTURE-ACTIVITY RELATIONSHIP STUDIES ON SOME SULFONAMIDES BEARING PIPERIDINE NUCLEUS

KHALID H.¹, AZIZ-UR-REHMAN^{1,*}, ABBASI M.A.¹, KHAN K.M.²

¹Department of Chemistry, Government College University, Lahore-54000, Pakistan. ²HEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan. E-mail: azizryk@yahoo.com

Received: 09 Mar 2012, Revised and Accepted: 15 Apr 2012

ABSTRACT

In the present study, a series of sulfonamides (**3a-k**) were synthesized by the coupling of different sulfonyl chloride (**1a-k**) with 4-(piperidin-1-yl)aniline (**2**) under dynamic pH control in aqueous media. Further, each of the synthesized sulfonamide treated with electrophile, ethyl iodide yielded *N*-ethyl substituted sulfonamides (**5a-k**) in the presence of sodium hydride (NaH) and dimethyl formamide (DMF). The structures of all the synthesized compounds were characterized by IR, EI-MS and ¹H-NMR spectra. To study the structure-activity relationship, these compounds were assayed for their antioxidant activities and other biological activities via screening them against acetylcholinesterase, butyrylcholinesterase and lipoxygenase enzymes. It was observed from the results that the *N*-ethyl substitution retarded their inhibitory potential while the unsubstituted molecules were relatively more suitable target for the treatment of Alzheimer's disease.

Keywords: 4-(piperidin-1-yl) aniline, Sulfonamides, Enzyme inhibition activity, ¹H-NMR and EI-MS.

INTRODUCTION

Several thousand of piperidine compounds have been cited in clinical and preclinical studies. Besides the appealing structural features, these compounds are also of pharmaceutical attention as they exhibit an extensive range of biological activities. The Piperidine nucleus is a ubiquitous structural feature in several pharmacologically active compounds, for example berberine and hydrastine which are natural medicinally important alkaloids.¹⁻⁴ There are loads of piperidine containing compounds which possess remarkable biological and medicinal properties.^{5,6} Piperidine has diverse applications in commercial and curative area. Piperidine and Pyrrolidine nucleus containing compounds showed their appreciable effect on plasma glucose level⁷, Insulin normalization, cure of cocaine abuse.⁸

Piperidine is also active as local anesthetics, such as mepivacaine, ropivacaine, and bupivacaine are extensively used in clinical practice.^{9,10} Sulfonamides are in use as restorative agents from many years. Very first use of sulfonamides was as antibacterial agent, but their uses have unmitigated to treat other diseases. Sulfonamides are also prominent for enzyme inhibition such as carbonic anhydrase, cysteine protease, HIV protease and cyclooxygenase.¹¹ Moreover; sulfonamides have extensive potential to other therapeutic applications i.e. in cancer chemotherapy, hypoglycaemia, and diuretics.¹² Pharmacological potential of these heterocyclic compounds provoked chemists to synthesized piperidine derivatives with enhanced biological activities.¹³

Acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8) consist of an enzymes family which includes serine hydrolases. The diverse specificities for the substrates and inhibitors for these enzymes are due to the differences in amino acid residues of the active sites of AChE and BChE. Actually the system of enzyme is responsible for the termination of acetylcholine at cholinergic synapses. These are key components of cholinergic brain synapses and neuromuscular junctions. The major function of AChE and BChE is to catalyze the hydrolysis of the neurotransmitter acetylcholine and termination of the nerve impulse in cholinergic synapses.^{14,15} It has been found that BChE is present in appreciably higher quantity in Alzheimer's plaques than in the normal age linked dementia of brains. H₁ and H₂ receptor antagonists possess AChE inhibitory activities. Cholinesterase inhibitors raise the quantity of acetylcholine available for neuronal and neuromuscular transmission through their ability to reversibly or irreversibly. Hence, the search for new cholinesterase inhibitors is considered an important and ongoing strategy to introduce new drug candidates for the treatment of Alzheimer's disease and other related diseases.^{16,17}

The present work is a successful effort to synthesize such novel compounds exhibiting diverse and improved pharmacological potential. We have synthesized the sulfonamides of piperidine to fuse two highly biological actives classes with an objective to search new contenders of drug having significant enhanced activity and could be helpful in controlling many degenerative diseases.

MATERIALS AND METHODS

Reagents

Melting points of the synthesized compounds were recorded on a Griffin and George melting point apparatus by open capillary tube and were uncorrected. Purity was checked on thin layer chromatography (TLC) on pre-coated silica gel G-25-UV₂₅₄ plates with different solvent systems using ethyl acetate and *n*-hexane giving single spot. Detection was carried out at 254 nm, and by ceric sulphate reagent. The I.R. spectra were recorded in KBr pellet method on a Jasco-320-A spectrophotometer (wave number in cm⁻¹). Nuclear magnetic resonance spectra were recorded in CD₃OD on a Bruker spectrometers operating at 300 MHz. Chemical shifts are given in ppm. Mass spectra (EIMS) were recorded on a JMS-HX-110 spectrometer, with a data system.

4-(piperidine-1-yl)aniline, sulfonyl chlorides and ethyl iodide were obtained from commercial suppliers. All the employed solvents were of analytical grade.

General procedure for the synthesis of *N*-(4-piperidin-1-ylphenyl)sulfonamides in aqueous medium (**3a-k**)

4-(piperidine-1-yl)aniline (**2**) (0.5 mL, 0.47 mmol) was suspended in 10 mL water and the pH was maintained at 9.0 by adding basic aqueous solution of a Na₂CO₃ at 0-5°C. Then, sulfonyl chlorides **1a-k** (0.47 mmol) was added in the reaction mass slowly over 10-15-min. After complete addition, the temperature of the reaction mixture was allowed to rise slowly to room temperature. The reaction mixture was stirred and monitored with TLC for the completion of reaction. Then conc. HCl (around 0.5 mL) was added slowly to adjust the pH to 2.0. The reaction mass was cooled to room temperature (RT), filtered and the solid washed with distilled water to afford the title compounds **3a-k** on drying.

General procedure for the synthesis of *N*-ethyl substituted sulfonamides (**5a-k**)

To an individual solution of compounds **3a-k** (0.02 g, 0.83 mmol) in *N,N*-dimethyl formamide (DMF) (0.5 mL), sodium hydride (0.001 g, 0.040 mmol) was added at room temperature and stirred for 15 min. The ethyl iodide (**4**) (0.061ml, 0.83 mmol) was added into the

reaction mixture and stirred for 30-40 min. The reaction mass was then monitored by TLC. After complete conversion, the reaction mass was quenched with cold water (20 mL). The obtained solid was filtered, washed with distilled water and dried to yield the corresponding *N*-ethyl sulfonamide derivatives **5a-k**.

Spectral Characterization of the Synthesized Compounds

N-[4-(Piperidin-1-yl)phenyl]benzenesulfonamide (3a)

Dirty green powder; Yield: 90%; M.p. 132-134°C. Molecular formula: C₁₇H₂₀N₂O₂S; Mol. Wt. 316g. IR (KBr, cm⁻¹) ν_{max}: 3429 (N-H stretching), 3023 (C-H stretching of aromatic ring), 1546 (C=C aromatic stretching), 1341 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 7.68 (dd, *J* = 2.5, 8.4 Hz, 2H, H-2" & H-6"), 7.46-7.41 (m, 1H, H-4"), 7.54-7.51 (m, 2H, H-3" & H-5"), 6.92 (d, *J* = 9.0 Hz, H-2 & 6), 6.82 (d, *J* = 9.0 Hz, H-3 & 5), 3.05 (t, *J* = 5.7 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 2.55 (t, *J* = 5.7 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 1.70 (m, 2H, CH₂-4'), 1.58 (m, 4H, CH₂-3' & CH₂-5'). EIMS: *m/z* 316 (19%) [M]⁺, 252 (21%), 175 (37%), 156 (24%), 141 (100%).

N-[4-(Piperidin-1-yl)phenyl]-4-methylbenzenesulfonamide (3b)

Grey sticky solid; Yield: 89%; Molecular formula: C₁₈H₂₂N₂O₂S; Mol. Wt. 330g IR (KBr, cm⁻¹) ν_{max}: 3424 (N-H stretching), 3018 (C-H stretching of aromatic ring), 1539 (C=C aromatic stretching), 1349 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 7.56 (d, *J* = 8.4 Hz, 2H, H-2" & H-6"), 7.26 (d, *J* = 8.4 Hz, 2H, H-3" & 5"), 6.93 (d, *J* = 9.0 Hz, H-2 & 6), 6.85 (d, *J* = 9.0 Hz, H-3 & 5), 3.07 (t, *J* = 5.1 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 2.95 (t, *J* = 5.1 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 2.35 (s, 3H, CH₃-4'), 1.68 (m, 2H, CH₂-4'), 1.56 (m, 4H, CH₂-3' & CH₂-5'). EIMS: *m/z* 330 (13%) [M]⁺, 266 (22%), 175(42%), 155 (51%), 91(100%; loss of tropylium ion fragment).

N-[4-(Piperidin-1-yl)phenyl]-1-phenylmethanesulfonamide (3c)

Black shiny solid; Yield: 87.5%; m.p 263-265°C. Molecular formula: C₁₈H₂₂N₂O₂S; Mol. Wt. 330g. IR (KBr, cm⁻¹) ν_{max}: 3417 (N-H stretching), 3034 (C-H stretching of aromatic ring), 1557 (C=C aromatic stretching), 1235 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 7.43 (m, 5H, H-2" to H-6"), 6.96 (d, *J* = 8.4 Hz, H-2 & 6), 6.70 (d, *J* = 8.4 Hz, H-3 & 5), 4.40 (s, 2H, SO₂-CH₂), 3.10 (t, *J* = 5.4 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 2.87 (t, *J* = 5.4 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 1.70 (m, 2H, CH₂-4'), 1.59 (m, 4H, CH₂-3' & CH₂-5'). EIMS: *m/z* 330 (13%) [M]⁺, 266 (22%), 175(42%), 155 (51%), 91(100%; loss of tropylium ion fragment).

N-[4-((4-Piperidin-1-yl)phenyl)acetamido]benzenesulfonamide (3d)

Bottled green sticky solid; Yield: 85%; Molecular formula: C₁₉H₂₃N₃O₃S; Mol. Wt. 373g. IR (KBr, cm⁻¹) ν_{max}: 3423 (N-H stretching), 3031 (C-H stretching of aromatic ring), 1543 (C=C aromatic stretching), 1337 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 7.62 (d, *J* = 8.7 Hz, 2H, H-2" & H-6"), 7.35 (d, *J* = 8.7 Hz, 2H, H-3" & 5"), 6.92 (d, *J* = 9.0 Hz, 2H, H-2 & 6), 6.82 (d, *J* = 9.0 Hz, 2H, H-3 & 5), 3.53 (t, *J* = 5.4 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 3.07 (t, *J* = 5.4 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 2.12 (s, 3H, CO-CH₃) 1.70 (m, 2H, CH₂-4'), 1.58 (m, 4H, CH₂-3' & CH₂-5'). EIMS: *m/z* 373 (13%) [M]⁺, 330 (27%), 309 (12%), 175 (32%), 155 (100%).

N-[4-(Piperidin-1-yl)phenyl]-4-acetylbenzenesulfonamide (3e)

Aqua green solid; Yield: 77%; m.p 140-142°C. Molecular formula: C₁₉H₂₂N₂O₃S; Mol. Wt. 358g. IR (KBr, cm⁻¹) ν_{max}: 3427 (N-H stretching), 3021 (C-H stretching of aromatic ring), 1549 (C=C aromatic stretching), 1347 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 8.05 (d, *J* = 8.7 Hz, 2H, H-2" & H-6"), 7.93 (d, *J* = 8.7 Hz, 2H, H-3" & 5"), 7.81 (d, *J* = 8.4 Hz, 2H, H-2 & 6), 7.00 (d, *J* = 8.4 Hz, 2H, H-3 & 5), 3.40 (t, *J* = 5.4 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 2.87 (t, *J* = 5.4 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 2.59 (s, 3H, CO-CH₃) 1.70 (m, 2H, CH₂-4'), 1.59 (m, 4H, CH₂-3' & CH₂-5'). EIMS: *m/z* 358 (15%) [M]⁺, 294 (23%), 315 (40%), 183 (19%), 119 (100%).

N-[4-(Piperidin-1-yl)phenyl]-2,4,6-trimethylbenzenesulfonamide (3f)

Black shiny sticky solid; Yield: 88%; Molecular formula: C₂₀H₂₆N₂O₂S; Mol. Wt. 358g. IR (KBr, cm⁻¹) ν_{max}: 3427 (N-H stretching), 3021 (C-H stretching of aromatic ring), 1547 (C=C

aromatic stretching), 1331 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 7.20 (d, *J* = 9.0 Hz, 2H, H-2 & 6), 7.12 (d, *J* = 9.0 Hz, 2H, H-3 & 5), 6.85 (s, 2H, H-3" & H-5"), 3.47 (t, *J* = 5.1 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 2.86 (t, *J* = 5.1 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 2.60 (s, CH₃-4") 1.95 (m, 2H, CH₂-4'), 1.67 (m, 4H, CH₂-3' & CH₂-5'). EIMS: *m/z* 358 (7%) [M]⁺, 294 (19%), 183 (23%), 175 (19%), 119 (100%).

N-[4-(Piperidin-1-yl)phenyl]-4-chlorobenzenesulfonamide (3g)

Dirty green solid; Yield: 89%; m.p 150-152°C. Molecular formula: C₁₇H₁₉ClN₂O₂S; Mol. Wt. 350g. IR (KBr, cm⁻¹) ν_{max}: 3419 (N-H stretching), 3031 (C-H stretching of aromatic ring), 1543 (C=C aromatic stretching), 1337 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 7.64 (d, *J* = 8.7 Hz, 2H, H-2" & H-6"), 7.47 (d, *J* = 8.7 Hz, 2H, H-3" & 5"), 6.93 (d, *J* = 9.0 Hz, 2H, H-2 & 6), 6.85 (d, *J* = 9.0 Hz, 2H, H-3 & 5), 3.08 (t, *J* = 5.1 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 2.88 (t, *J* = 5.1 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 1.67 (m, 2H, CH₂-4'), 1.57 (m, 4H, CH₂-3' & CH₂-5'). EIMS: *m/z* 350 (19%) [M]⁺, 286 (29%), 190 (42%), 175 (51%), 111 (100%).

N-[4-(Piperidin-1-yl)phenyl]-2,3-dihydro-1,4-benzodioxine-6-sulfonamide (3h)

Roil blue sticky solid; Yield: 86.5%; Molecular formula: C₁₉H₂₂N₂O₄S; Mol. Wt. 374g. IR (KBr, cm⁻¹) ν_{max}: 3429 (N-H stretching), 3023 (C-H stretching of aromatic ring), 1546 (C=C aromatic stretching), 1341 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 7.29 (dd, *J* = 2.0, 8.4 Hz, 1H, H-1"), 7.25 (d, *J* = 8.4 Hz, 1H, H-2"), 7.21 (d, *J* = 8.4 Hz, 1H, H-6"), 6.90 (d, *J* = 9.0 Hz, 2H, H-2 & 6), 6.84 (d, *J* = 9.0 Hz, 2H, H-3 & 5), 4.30-4.34 (m, 4H, O-CH₂-CH₂-O), 3.43 (t, *J* = 5.4 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 2.98 (t, *J* = 5.4 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 1.67 (m, 2H, CH₂-4'), 1.57 (m, 4H, CH₂-3' & CH₂-5'). EIMS: *m/z* 374 (13%) [M]⁺, 310 (17%), 199 (37%), 175 (45%), 135 (100%).

N-[4-(Piperidin-1-yl)phenyl]-3,5-dichloro-2-hydroxybenzenesulfonamide (3i)

Magenta shiny crystals; Yield: 90%; m.p 200-202°C. Molecular formula: C₁₇H₁₈Cl₂N₂O₃S; Mol. Wt. 401g. IR (KBr, cm⁻¹) ν_{max}: 3421 (N-H stretching), 3025 (C-H stretching of aromatic ring), 1547 (C=C aromatic stretching), 1343 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 7.70 (d, *J* = 2.7 Hz, 1H, H-6"), 7.61 (d, *J* = 2.7 Hz, 1H, H-4"), 7.53 (d, *J* = 7.2 Hz, 2H, H-2 & 6), 7.37 (d, *J* = 7.2 Hz, 2H, H-3 & 5), 3.66 (t, *J* = 5.1 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 3.54 (t, *J* = 5.1 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 2.05 (m, 2H, CH₂-4'), 1.81 (m, 4H, CH₂-3' & CH₂-5'). EIMS: *m/z* 401 (19%) [M]⁺, 337 (29%), 241 (42%), 175 (51%), 161 (100%).

N-[4-(Piperidin-1-yl)phenyl]camphor-8-sulfonamide (3j)

Buff sticky solid; Yield: 84%; Molecular formula: C₂₁H₃₀N₂O₃S; Mol. Wt. 390g IR (KBr, cm⁻¹) ν_{max}: 3429 (N-H stretching), 3023 (C-H stretching of aromatic ring), 1546 (C=C aromatic stretching), 1341 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 6.93 (d, *J* = 9.0 Hz, 2H, H-2 & 6), 6.85 (d, *J* = 9.0 Hz, 2H, H-3 & 5), 3.51 (m, 2H, CH₂-SO₂), 3.08 (t, *J* = 5.1 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 2.88 (t, *J* = 5.1 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 1.67 (m, 2H, CH₂-4'), 1.60-2.51 (m, 7H, CHCH₂CH₂CHCH of camphor), 1.57 (m, 4H, CH₂-3' & CH₂-5'), 1.05 (s, 3H, -CH₃ of camphor), 0.82 (s, 3H, -CH₃ of camphor). EIMS: *m/z* 390 (19%) [M]⁺, 326 (29%), 215 (42%), 175 (51%), 151(100%).

N-[4-(Piperidin-1-yl)phenyl]butane-1-sulfonamide (3k)

Light green sticky solid; Yield: 87%; Molecular formula: C₁₅H₂₄N₂O₂S; Mol. Wt. 296g. IR (KBr, cm⁻¹) ν_{max}: 3427 (N-H stretching), 3021 (C-H stretching of aromatic ring), 1543 (C=C aromatic stretching), 1343 (-SO₂- stretching); ¹H-NMR (300 MHz, CD₃OD, δ / ppm): 6.92 (d, *J* = 8.2 Hz, 2H, H-2 & 6), 6.82 (d, *J* = 8.2 Hz, 2H, H-3 & 5), 3.10 (t, *J* = 5.4 Hz, 2H, H_{ax}-2' & H_{ax}-6'), 2.87 (t, *J* = 5.4 Hz, 2H, H_{eq}-2' & H_{eq}-6'), 2.91 (t, *J* = 7.0 Hz, 2H, CH₂-1"), 2.05 (m, 2H, CH₂-4'), 1.81 (m, 4H, CH₂-3' & CH₂-5'), 1.68-1.48 (m, 4H, CH₂-2" to CH₂-3"), 0.94 (t, *J* = 3.6 Hz, 3H, CH₃-4"). EIMS: *m/z* 296 (19%) [M]⁺, 232 (29%), 175 (42%), 121 (100%).

N-Ethyl-*N*-[4-(piperidin-1-yl)phenyl]benzenesulfonamide (5a)

Violet sticky solid; Yield: 80%; Molecular formula: $C_{19}H_{24}N_2O_2S$; Mol. Wt. 344g. IR (KBr, cm^{-1}) ν_{max} : 3028 (C-H stretching of aromatic ring), 1542 (C=C aromatic stretching), 1344 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 7.64 (dd, $J = 2.5, 8.4$ Hz, 2H, H-2" & H-6"), 7.42-7.39 (m, 1H, H-4"), 7.52-7.54 (m, 2H, H-3" & H-5"), 6.91 (d, $J = 9.0$ Hz, H-2 & 6), 6.83 (d, $J = 9.0$ Hz, H-3 & 5), 3.61 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.05 (t, $J = 5.7$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 2.55 (t, $J = 5.7$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 1.70 (m, 2H, CH_2-4'), 1.58 (m, 4H, CH_2-3' & CH_2-5'), 1.05 (t, $J = 7.2$ Hz, 3H, CH_3-2''). EIMS: m/z 344 (12%) $[M]^+$, 280 (31%), 203 (24%), 141(100%).

N-Ethyl-N-[4-(Piperidin-1-yl)phenyl]-4-methylbenzene sulfonamide (5b)

Black sticky solid; Yield: 86.5%; Molecular formula: $C_{20}H_{26}N_2O_2S$; Mol. Wt. 358g. IR (KBr, cm^{-1}) ν_{max} : 3021 (C-H stretching of aromatic ring), 1542 (C=C aromatic stretching), 1344 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 7.58 (d, $J = 8.4$ Hz, 2H, H-2" & H-6"), 7.24 (d, $J = 8.4$ Hz, 2H, H-3" & 5"), 6.91 (d, $J = 9.0$ Hz, H-2 & 6), 6.83 (d, $J = 9.0$ Hz, H-3 & 5), 3.60 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.12 (t, $J = 5.1$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 2.99 (t, $J = 5.1$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 2.38 (s, 3H, CH_3-4''), 1.69 (m, 2H, CH_2-4'), 1.57 (m, 4H, CH_2-3' & CH_2-5'), 1.03 (t, $J = 7.2$ Hz, 3H, CH_3-2''). EIMS: m/z : 358 (8%) $[M]^+$, 294(12%), 203(31%), 155 (26%), 91(100%; loss of tropylium ion fragment).

N-Ethyl-N-[4-(Piperidin-1-yl)phenyl]-1-phenylmethane sulfonamide (5c)

Black sticky solid; Yield: 85%; Molecular formula: $C_{20}H_{26}N_2O_2S$; Mol. Wt. 359g. IR (KBr, cm^{-1}) ν_{max} : 3021 (C-H stretching of aromatic ring), 1557 (C=C aromatic stretching), 1331 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 7.44 (m, 5H, H-2" to H-6"), 6.93 (d, $J = 8.4$ Hz, H-2 & 6), 6.71 (d, $J = 8.4$ Hz, H-3 & 5), 4.42 (s, 2H, SO_2-CH_2), 3.59 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.11 (t, $J = 5.4$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 2.89 (t, $J = 5.4$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 1.75 (m, 2H, CH_2-4'), 1.57 (m, 4H, CH_2-3' & CH_2-5'), 1.01 (t, $J = 7.2$ Hz, 3H, CH_3-2''). EIMS: m/z 358 (5%) $[M]^+$, 294(23%), 203(39%), 155 (21%), 91(100%; loss of tropylium ion fragment).

N-Ethyl-N-[4-(4-(piperidin-1-yl)phenyl)acetamido]benzene sulfonamide (5d)

Shumpain sticky solid; Yield: 81%; Molecular formula: $C_{21}H_{27}N_3O_3S$; Mol. Wt. 401g. IR (KBr, cm^{-1}) ν_{max} : 3019 (C-H stretching of aromatic ring), 1537 (C=C aromatic stretching), 1333 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 7.65 (d, $J = 8.7$ Hz, 2H, H-2" & H-6"), 7.39 (d, $J = 8.7$ Hz, 2H, H-3" & 5"), 6.90 (d, $J = 9.0$ Hz, 2H, H-2 & 6), 6.81 (d, $J = 9.0$ Hz, 2H, H-3 & 5), 3.63 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.55 (t, $J = 5.4$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 3.05 (t, $J = 5.4$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 2.17 (s, 3H, $CO-CH_3$) 1.71 (m, 2H, CH_2-4'), 1.55 (m, 4H, CH_2-3' & CH_2-5'), 1.07 (t, $J = 7.2$ Hz, 3H, CH_3-2''). EIMS: m/z : 401 (7%) $[M]^+$, 358 (17%), 337 (52%), 203 (22%), 155 (100%).

N-Ethyl-N-(4-(piperidin-1-yl)phenyl)-4-acetylbenzenesulfonamide (5e)

Sea-green sticky solid; Yield: 78%; m.p 87-89 °C, Molecular formula: $C_{21}H_{26}N_2O_3S$; Mol. Wt. 386g. IR (KBr, cm^{-1}) ν_{max} : 3019 (C-H stretching of aromatic ring), 1537 (C=C aromatic stretching), 1335 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 8.01 (d, $J = 8.7$ Hz, 2H, H-2" & H-6"), 7.97 (d, $J = 8.7$ Hz, 2H, H-3" & 5"), 7.81 (d, $J = 8.4$ Hz, 2H, H-2 & 6), 7.01 (d, $J = 8.4$ Hz, 2H, H-3 & 5), 3.59 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.43 (t, $J = 5.4$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 2.89 (t, $J = 5.4$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 2.57 (s, 3H, $CO-CH_3$) 1.71 (m, 2H, CH_2-4'), 1.57 (m, 4H, CH_2-3' & CH_2-5'), 1.10 (t, $J = 7.2$ Hz, 3H, CH_3-2''). EIMS: m/z : 386 (15%) $[M]^+$, 343 (23%), 322 (40%), 203 (19%), 119 (100%).

N-Ethyl-N-(4-(piperidin-1-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide (5f)

Black sticky solid; Yield: 88%; Molecular formula: $C_{22}H_{30}N_2O_2S$; Mol. Wt. 386g. IR (KBr, cm^{-1}) ν_{max} : 3021 (C-H stretching of aromatic ring), 1543 (C=C aromatic stretching), 1340 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 7.19 (d, $J = 9.0$ Hz, 2H, H-2 & 6), 7.13 (d, $J = 9.0$ Hz, 2H, H-3 & 5), 6.87 (s, 2H, H-3" & H-5"), 3.63 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.45 (t, $J = 5.1$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 2.83 (t, $J = 5.1$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 2.63 (s, CH_3-4'') 1.97 (m, 2H, CH_2-4'), 1.63 (m, 4H, CH_2-3' & CH_2-5'), 1.03 (t, $J = 7.2$ Hz, 3H, CH_3-2''). EIMS: m/z 386 (7%) $[M]^+$, 322 (19%), 203 (23%), 183 (19%), 119 (100%).

Dark green sticky solid; Yield: 85%; m.p 90-93°C, Molecular formula: $C_{19}H_{23}ClN_2O_2S$; Mol. Wt. 378g. IR (KBr, cm^{-1}) ν_{max} : 3033 (C-H stretching of aromatic ring), 1541 (C=C aromatic stretching), 1337 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 7.61 (d, $J = 8.7$ Hz, 2H, H-2" & H-6"), 7.49 (d, $J = 8.7$ Hz, 2H, H-3" & 5"), 6.91 (d, $J = 9.0$ Hz, 2H, H-2 & 6), 6.87 (d, $J = 9.0$ Hz, 2H, H-3 & 5), 3.63 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.07 (t, $J = 5.1$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 2.89 (t, $J = 5.1$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 1.65 (m, 2H, CH_2-4'), 1.59 (m, 4H, CH_2-3' & CH_2-5'), 1.0q (t, $J = 7.2$ Hz, 3H, CH_3-2''). EIMS: m/z 378 (7%) $[M]^+$, 314 (17%), 203 (27%), 175 (15%), 111 (100%).

N-Ethyl-N-(4-(piperidin-1-yl)phenyl)-4-chlorobenzenesulfonamide (5g)

Deep blue sticky solid; Yield: 86%; Molecular formula: $C_{21}H_{26}N_2O_4S$; Mol. Wt. 402g. IR (KBr, cm^{-1}) ν_{max} : 3029 (C-H stretching of aromatic ring), 1541 (C=C aromatic stretching), 1333 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 7.33 (dd, $J = 2.0, 8.4$ Hz, 1H, H-1"), 7.27 (d, $J = 8.4$ Hz, 1H, H-2"), 7.20 (d, $J = 8.4$ Hz, 1H, H-6"), 6.91 (d, $J = 9.0$ Hz, 2H, H-2 & 6), 6.83 (d, $J = 9.0$ Hz, 2H, H-3 & 5), 4.31-4.35 (m, 4H, O- CH_2-CH_2-O), 3.63 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.45 (t, $J = 5.4$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 2.99 (t, $J = 5.4$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 1.66 (m, 2H, CH_2-4'), 1.59 (m, 4H, CH_2-3' & CH_2-5'), 1.01 (t, $J = 7.2$ Hz, 3H, CH_3-2''). EIMS: m/z 402 (11%) $[M]^+$, 338 (14%), 203 (27%), 199 (35%), 135 (100%).

N-Ethyl-N-(4-(piperidin-1-yl)phenyl)-2,3-dihydro-1,4-benzodioxine-6-sulfonamide (5h)

Purple coloured sticky solid; Yield: 89%; Molecular formula: $C_{19}H_{22}Cl_2N_2O_3S$; Mol. Wt. 429g. IR (KBr, cm^{-1}) ν_{max} : 3035 (C-H stretching of aromatic ring), 1527 (C=C aromatic stretching), 1335 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 7.73 (d, $J = 2.7$ Hz, 1H, H-6"), 7.67 (d, $J = 2.7$ Hz, 1H, H-4"), 7.51 (d, $J = 7.2$ Hz, 2H, H-2 & 6), 7.35 (d, $J = 7.2$ Hz, 2H, H-3 & 5), 3.65 (t, $J = 5.1$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 3.63 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.57 (t, $J = 5.1$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 2.01 (m, 2H, CH_2-4'), 1.83 (m, 4H, CH_2-3' & CH_2-5'), 1.03 (t, $J = 7.2$ Hz, 3H, CH_3-2''). EIMS: m/z 401 (13%) $[M]^+$, 365 (22%), 269 (15%), 203 (65%), 161 (100%).

N-Ethyl-N-(4-(piperidin-1-yl)phenyl)-3,5-dichloro-2-hydroxy benzenesulfonamide (5i)

Black sticky solid; Yield: 64%; Molecular formula: $C_{23}H_{34}N_2O_3S$; Mol. Wt. 418g. IR (KBr, cm^{-1}) ν_{max} : 3025 (C-H stretching of aromatic ring), 1539 (C=C stretching of aromatic ring), 1335 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 6.91 (d, $J = 9.0$ Hz, 2H, H-2 & 6), 6.83 (d, $J = 9.0$ Hz, 2H, H-3 & 5), 3.60 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.53 (m, 2H, CH_2-SO_2), 3.09 (t, $J = 5.1$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 2.79 (t, $J = 5.1$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 1.69 (m, 2H, CH_2-4'), 1.62-2.53 (m, 7H, $CHCH_2CH_2CHCH$ of camphor), 1.51 (m, 4H, CH_2-3' & CH_2-5'), 1.07 (t, $J = 7.2$ Hz, 3H, CH_3-2''), 1.01 (s, 3H, $-CH_3$ of camphor), 0.82 (s, 3H, $-CH_3$ of camphor). EIMS: m/z 390 (4%) $[M]^+$, 354 (17%), 215 (22%), 203 (31%), 151(100%).

N-Ethyl-N-(4-(piperidin-1-yl)phenyl)camphor-8-sulfonamide (5j)

Green sticky solid; Yield: 82%; Molecular formula: $C_{17}H_{18}N_2O_2S$; Mol. Wt. 324g. IR (KBr, cm^{-1}) ν_{max} : 3021 (C-H stretching of aromatic ring), 1535 (C=C aromatic stretching), 1343 ($-SO_2$ stretching); 1H -NMR (300 MHz, CD_3OD , δ / ppm): 6.91 (d, $J = 8.2$ Hz, 2H, H-2 & 6), 6.85 (d, $J = 8.2$ Hz, 2H, H-3 & 5), 3.63 (q, $J = 7.2$ Hz, 2H, CH_2-1''), 3.11 (t, $J = 5.4$ Hz, 2H, $H_{ax}-2'$ & $H_{ax}-6'$), 2.99 (t, $J = 5.4$ Hz, 2H, $H_{eq}-2'$ & $H_{eq}-6'$), 2.93 (t, $J = 7.0$ Hz, 2H, CH_2-1''), 2.01 (m, 2H, CH_2-4'), 1.83 (m, 4H, CH_2-3' & CH_2-5'), 1.63-1.49 (m, 4H, CH_2-2'' to CH_2-3''), 1.00 (t, $J = 7.2$ Hz, 3H, CH_3-2''), 0.91 (t, $J = 3.6$ Hz, 3H, CH_3-4''). EIMS: m/z 324 (11%) $[M]^+$, 260 (17%), 203(35%), 121 (100%).

N-Ethyl-N-(4-(piperidin-1-yl)phenyl)butane-1-sulfonamide (5k)

Enzyme Inhibition Assays

Acetylcholinesterase Assay

The AChE inhibition activity was performed according to the method¹⁸ with slight modifications. Total volume of the reaction mixture was 100 μ L. It contained 60 μ L Na_2HPO_4 buffer with concentration of 50 mM and pH 7.7. 10 μ L test compound (0.5 mM well⁻¹) was added, followed by the addition of 10 μ L (0.005 unit well⁻¹) enzyme. The contents were mixed and pre-read at 405 nm. Then contents were pre-incubated for 10 min at 37°C. The reaction was initiated by the addition of 10 μ L of 0.5 mM well⁻¹ substrate (acetylthiocholine iodide), followed by the addition of 10 μ L DTNB (0.5 mM well⁻¹). After 15 min of incubation at 37°C absorbance was measured at 405 nm using 96-well plate reader Synergy HT, Biotek, USA. All experiments were carried out with their respective controls in triplicate. Eserine (0.5 mM well⁻¹) was used as a positive control. The percent inhibition was calculated by the help of following equation

$$\text{Inhibition (\%)} = \frac{\text{Control} - \text{Test}}{\text{Control}} \times 100$$

IC_{50} values were calculated using EZ-Fit Enzyme kinetics software (Perrella Scientific Inc. Amherst, USA).

Butyrylcholinesterase Assay

The BChE inhibition activity was performed according to the method¹⁸ with slight modifications. Total volume of the reaction mixture was 100 μ L containing 60 μ L, Na_2HPO_4 buffer, 50 mM and pH 7.7. 10 μ L test compound 0.5 mM well⁻¹ was added followed by the addition of 10 μ L (0.5 unit well⁻¹) BChE (Sigma Inc.). The contents were mixed and pre-read at 405 nm and then pre-incubated for 10 min at 37°C. The reaction was initiated by the addition of 10 μ L of 0.5 mM well⁻¹ substrate (butyrylthiocholine chloride). Followed by the addition of 10 μ L DTNB, 0.5 mM well⁻¹. After 15 min of incubation at 37°C, absorbance was measured at 405 nm using 96-well plate reader Synergy HT, Biotek, USA. All experiments were carried out with their respective controls in triplicate. Eserine (0.5 mM well⁻¹) was used as positive control. The percent inhibition was calculated by the help of following equation.

$$\text{Inhibition (\%)} = \frac{\text{Control} - \text{Test}}{\text{Control}} \times 100$$

IC_{50} values were calculated using EZ-Fit Enzyme kinetics software (Perrella Scientific Inc. Amherst, USA).

Lipoxygenase Assay

Lipoxygenase (LOX) activity was assayed according to the method¹⁹⁻²¹ with slight modifications. A total volume of 200 μ L lipoxygenase assay mixture contained 150 μ L sodium phosphate buffer (100 mM, pH 8.0), 10 μ L test compound and 15 μ L purified lipoxygenase enzyme (600 units well⁻¹, Sigma Inc.). The contents were mixed and pre-read at 234 nm and preincubated for 10 minutes at 25°C. The reaction was initiated by addition of 25 μ L substrate solution. The change in absorbance was observed after 6 min at 234 nm using 96-well plate reader Synergy HT, Biotek, USA. All reactions were performed in triplicates. The positive and negative controls were included in the assay. Baicalin (0.5 mM well⁻¹) was used as a positive control. The percentage inhibition (%) was calculated by formula given below.

$$\text{Inhibition (\%)} = \frac{\text{Control} - \text{Test}}{\text{Control}} \times 100$$

Where Control = Total enzyme activity without inhibitor

Test = Activity in the presence of test compound

IC_{50} values were calculated using EZ-Fit Enzyme Kinetics software (Perrella Scientific Inc. Amherst, USA).

DPPH Assay

The stable 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) was used for the determination of antioxidant activity. Different concentrations of compounds in respective solvents were added at an equal volume (10 μ L) to 90 μ L of 100 μ M methanolic DPPH in a total volume of 100 μ L in 96-well plates. The contents were mixed and incubated at 37°C for 30 minutes. The absorbance was

measured at 517nm using Synergy HT BioTek® USA microplate reader. Quercetin and L-ascorbic acid were used as standard antioxidants. The experiments were carried out in triplicates. IC_{50} values were calculated using EZ-Fit5 Perrella Scientific Inc. Amherst USA software. The decrease in absorbance indicates increased radical scavenging activity which was determined by the following formula.²²

$$\text{Antiradical activity (\% Inhibition)} = \frac{\text{Control} - \text{Test}}{\text{Control}} \times 100$$

Statistical Analysis

All the measurements were done in triplicate and statistical analysis was performed by Microsoft Excel 2003. Results are presented as mean \pm sem.

RESULTS AND DISCUSSION


The objective of our research work was to synthesize sulfonamides and further its *N*-ethyl substituted derivatives and to screen out their enzymatic activities. First, a series of sulfonamides (**3a-k**) were synthesized by the reaction of different sulfonyl chlorides (**1a-k**) with 4-(piperidin-1-yl)aniline (**2**) under dynamic pH control in aqueous media.^{23,24} Further, *N*-ethyl substituted sulfonamides (**5a-k**) were obtained by treating each of the sulfonamide with electrophile, ethyl iodide in the presence of *N,N*-dimethyl formamide (DMF) and sodium hydride (NaH) which acts as a base. Reactants completely converted into products by simple stirring after 1-3 hrs. Precipitates were quenched by treating with cold water and recrystallized by using methanol (Scheme-1). Compound **3a** was synthesized as dirty green powder. The molecular formula $\text{C}_{17}\text{H}_{20}\text{N}_2\text{O}_2\text{S}$ was established by molecular ion peak at m/z 316 in EI-MS and by counting the number of protons in its ¹H-NMR spectrum. The IR spectrum showed absorption bands at 1441 cm^{-1} , 3024 cm^{-1} , 3023 cm^{-1} and 1546 cm^{-1} which were assigned to, $-\text{SO}_2$ (stretching of sulfonyl group), SO_2 -N-H (stretching of sulfonamide), C-H (aromatic stretching) and C=C (stretching of aromatic ring) respectively. The EI-MS gave a distinct peak at m/z 252 after the removal of $-\text{SO}_2$ group and further a peak was observed at m/z 141 which showed the presence of benzenesulfonyl group in the molecule. In the aromatic region of the ¹H-NMR spectrum signals appeared at δ 7.68 (dd, $J = 2.5, 8.4$ Hz, 2H, H-2" & H-6"), 7.46-7.41 (m, 1H, H-4") and 7.54-7.51 (m, 2H, H-3" & H-5") which were assigned to the mono substituted aromatic ring. The two signals appeared at δ 6.92 (d, $J = 9.0$ Hz, 2H, H-2 & 6) and 6.82 (d, $J = 9.0$ Hz, 2H, H-3 & 5), due to large coupling constant and each signal integrated two protons showed that the presence of para disubstituted aromatic ring. In the aliphatic region of the ¹H-NMR spectrum, signals appeared at 3.05 (t, $J = 5.7$ Hz, 2H, $\text{H}_{\text{ax}}-2'$ & $\text{H}_{\text{ax}}-6'$), 2.55 (t, $J = 5.7$ Hz, 2H, $\text{H}_{\text{eq}}-2'$ & $\text{H}_{\text{eq}}-6'$), 1.70 (m, 2H, CH_2-4') and 1.58 (m, 4H, CH_2-3' & CH_2-5') which indicated the presence of piperidine nucleus in the molecule. On the basis of above cumulative evidences, the structure of **3a** was assigned as *N*-[4-(Piperidin-1-yl)phenyl]benzenesulfonamide. Similarly, the structures of other compounds were characterized by ¹H-NMR, IR and mass spectral data as described in experimental section.

Enzyme inhibition activity

The screening of these synthesized compounds against acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and lipoxygenase (LOX) enzymes revealed that these molecules exhibited good inhibitory potential against acetylcholinesterase and butyrylcholinesterase as it was evident from their IC_{50} values. The results are depicted in Table-1 & Table-2. It is clearly evident from results in table-1 that the compounds *N*-[4-((4-Piperidin-1-yl)phenyl)acetamido]benzenesulfonamide (**3d**) and *N*-[4-(Piperidin-1-yl)phenyl]-3,5-dichloro-2-hydroxybenzenesulfonamide (**3i**) were found to be promising inhibitors against acetylcholinesterase enzyme having IC_{50} value of 77.11 \pm 0.06 and 81.33 \pm 0.09 μ moles/L respectively, relative to Eserine, a reference standard with IC_{50} value of 0.04 \pm 0.001 μ moles, probably due to 4-acetamidophenyl and 2-hydroxy-3,5-dichlorophenyl groups respectively in these molecules. From table-2, the compounds **5c**, **5d** and **5f** were identified as good inhibitors having IC_{50} value of 35.41 \pm 0.15, 66.31 \pm 0.21 and 68.31 \pm 0.6309 μ moles/L respectively, as compared to reference standard. The enhanced activity might be due to *N*-substitution of

ethyl group in these sulfonamides. The screening against butyrylcholinesterase enzyme exposed that the compounds **3f** and **3b** (Table-1) exhibited talented inhibitory potential having IC_{50} value of 40.41 ± 0.61 and 45.11 ± 0.09 $\mu\text{moles/L}$ as compared to standard with IC_{50} value of 0.85 ± 0.0001 $\mu\text{moles/L}$, probably due to the present of 2,4,6-trimethylphenyl and 4-methylphenyl groups respectively in these molecules. However, some compounds (Table-1) showed weak inhibition against lipoxigenase enzyme but all other compounds remained inactive. Similarly the activity of compounds **5i** and **5j** (Table-2) showed excellent inhibitory potential having IC_{50} values of 27.11 ± 0.21 and 35.61 ± 0.05 $\mu\text{moles/L}$ respectively, as compared to reference standard. This enhanced activity might also be due to *N*-ethyl substitution of sulfonamides. DPPH is a stable free radical at room temperature. DPPH radical is scavenged by antioxidants through the donation of a proton and

form reduced DPPH. The colour changes from violet to yellow after reduction of DPPH, and it can be quantified by decrease of absorbance at wavelength 517 nm. Radical scavenging activity increased with increasing percentage of the free radical inhibition. The colour change from violet to yellow and fall in absorbance of the stable radical DPPH was measured for three different concentrations of samples, and the results are shown in table-1. These results revealed that the compound *N*-[4-(4-(Piperidin-1-yl)phenyl)acetamido]benzenesulfonamide (**3d**) showed good % scavenging of DPPH. One more concrete information from the data (Table-1 & 2), reflected that all the *N*-ethyl substituted sulfonamides (**5a-k**) lose their antioxidant activity. The IC_{50} value for each sample was calculated from the curves plotted. IC_{50} is the concentration of samples causing 50 percent inhibition of absorbance and lower its value means greater antioxidant activity of the samples.



| Compound | R | Compound | R | Compound | R |
|---------------|---|---------------|---|---------------|---|
| 3a, 5a | | 3e, 5e | | 3i, 5i | |
| 3b, 5b | | 3f, 5f | | 3j, 5j | |
| 3c, 5c | | 3g, 5g | | 3k, 5k | |
| 3d, 5d | | 3h, 5h | | | |

Scheme 1: Outline for the synthesis of sulfonamides 3a-k & 5a-k

Table 1: Bioactivity studies of sulfonamides (3a-k)

| Sample Code | DPPH | | AchE | | BchE | | LOX | |
|-------------|--|-------------------------|--|--------------------------------|--|-------------------------|--|-------------------------|
| | Inhibition (%) Conc./well (0.5 mM) | IC_{50} μM | Inhibition (%) Conc./well (0.5 mM) | IC_{50} ($\mu\text{mol.}$) | Inhibition (%) Conc./well (0.5 mM) | IC_{50} μM | Inhibition (%) Conc./well (0.5 mM) | IC_{50} μM |
| 3a | 24.78±0.51 | 139.41±0.18 | 71.64±0.11 | 132.21±0.04 | 93.67±0.12 | 51.61±0.04 | 11.27±0.01 | NIL |
| 3b | 71.07±0.87 | 159.11±0.14 | 82.94±0.41 | 89.51±0.04 | 92.66±0.41 | 45.11±0.09 | 64.44±0.17 | 270.51±0.04 |
| 5c | 76.31±0.49 | 134.41±0.51 | 69.08±0.44 | 110.71±0.62 | 88.19±0.23 | 81.11±0.03 | 69.60±0.19 | 304.91±0.01 |
| 3d | 89.53±0.32 | 48.11±0.56 | 79.96±0.51 | 77.11±0.06 | 75.52±0.61 | 130.81±0.51 | 3.40±0.11 | NIL |
| 3e | 77.14±0.13 | 134.51±0.08 | 79.32±0.05 | 125.71±0.21 | 95.91±0.99 | 39.81±0.71 | 39.20±0.13 | NIL |
| 3f | 73.69±0.11 | 153.51±0.61 | 66.10±0.51 | 230.81±0.62 | 91.74±0.55 | 40.41±0.61 | 63.03±0.51 | 294.51±0.11 |
| 3g | 75.67±0.21 | 142.71±0.21 | 78.89±0.24 | 214.11±0.71 | 83.71±0.52 | 122.21±0.26 | 75.23±0.41 | 142.71±0.21 |
| 3h | 59.77±0.81 | 348.21±0.18 | 70.36±0.01 | 197.21±0.81 | 95.83±0.74 | 50.11±0.61 | 61.27±0.91 | 339.41±0.18 |
| 3i | 69.92±0.17 | 184.11±0.25 | 82.52±0.14 | 81.33±0.09 | 79.38±0.26 | 143.41±0.33 | 19.84±0.62 | NIL |
| 3j | 65.95±0.75 | 260.51±0.04 | 84.43±0.29 | 124.21±0.51 | 89.85±0.24 | 132.41±0.36 | 43.78±0.25 | NIL |
| 3k | 83.59±0.89 | 117.51±0.15 | 87.21±0.11 | 113.11±0.25 | 94.29±0.48 | 47.61±0.62 | 61.38±0.89 | 324.11±0.15 |
| Control | Quercetin | 16.96±0.14 | Eserine | 0.04±0.001 | Eserine | 0.85±0.0001 | Baicalein | 22.4±1.3 |

Note: IC₅₀ values (concentration at which there is 50% enzyme inhibition) of compounds were calculated using EZ-Fit Enzyme kinetics software (Perella Scientific Inc. Amherst, USA).

AChE = Acetyl cholinesterase; BChE = Butyrylcholinesterase; LOX = Lipoxygenase; DPPH = 1,1-diphenyl-2-picrylhydrazyl radical.

Table 2: Bioactivity studies of *N*-ethyl substituted sulfonamides (5a-k)

| Sample Code | DPPH | | AChE | | BChE | | LOX | |
|-------------|---------------------------------------|---------------------|---------------------------------------|--------------------------|---------------------------------------|---------------------|---------------------------------------|---------------------|
| | Inhibition (%) Conc./well (0.5 mM) | IC ₅₀ μM | Inhibition (%) Conc./well (0.5 mM) | IC ₅₀ (μmol.) | Inhibition (%) Conc./well (0.5 mM) | IC ₅₀ μM | Inhibition (%) Conc./well (0.5 mM) | IC ₅₀ μM |
| 5a | 16.00±0.29 | NIL | 63.29±0.55 | 164.11±0.17 | 94.25±0.14 | 38.81±0.05 | 58.54±0.51 | <300 |
| 5b | 17.04±0.11 | NIL | 54.37±0.42 | <300 | 80.87±0.44 | 99.51±0.18 | 58.74±0.71 | <300 |
| 5c | 34.07±0.08 | NIL | 93.45±0.15 | 35.41±0.15 | 92.96±0.23 | 60.41±0.15 | 29.73±0.11 | NIL |
| 5d | 12.83±0.31 | NIL | 83.73±0.76 | 66.31±0.21 | 86.97±0.31 | 69.81±0.11 | 61.93±0.34 | <300 |
| 5e | 20.35±0.21 | NIL | 73.12±0.19 | 136.11±0.28 | 85.21±0.56 | 75.21±0.28 | 32.51±0.75 | NIL |
| 5f | 16.08±0.42 | NIL | 88.69±0.67 | 68.31±0.63 | 97.18±0.45 | 54.71±0.63 | 59.16±0.34 | <300 |
| 5g | 14.31±0.27 | NIL | 83.04±0.16 | 138.71±0.36 | 83.80±0.17 | 135.51±0.36 | 31.69±0.28 | NIL |
| 5h | 16.89±0.95 | NIL | 65.97±0.07 | 111.11±0.36 | 89.20±0.71 | 49.91±0.07 | 30.86±0.36 | NIL |
| 5i | 17.99±0.29 | NIL | 72.62±0.11 | 133.61±0.71 | 94.60±0.05 | 27.11±0.21 | 54.22±0.19 | <300 |
| 5j | 16.00±0.29 | NIL | 63.29±0.55 | 164.11±0.17 | 94.25±0.14 | 38.81±0.05 | 58.54±0.51 | <300 |
| 5k | 13.94±0.53 | NIL | 64.46±0.61 | 138.61±0.17 | 69.31±0.21 | 142.61±0.17 | 33.23±0.86 | NIL |
| Control | Quercetin 93.21±0.97 | 16.96±0.14 | Eserine 91.29±1.17 | 0.04±0.001 | Eserine 82.82±1.09 | 0.85±0.0001 | Baicalein 93.79±1.27 | 22.4±1.3 |

Note: IC₅₀ values (concentration at which there is 50% enzyme inhibition) of compounds were calculated using EZ-Fit Enzyme kinetics software (Perella Scientific Inc. Amherst, USA).

AChE = Acetyl cholinesterase; BChE = Butyrylcholinesterase; LOX = Lipoxygenase; DPPH = 1,1-diphenyl-2-picrylhydrazyl radical.

CONCLUSION

The proposed structures of the synthesized compounds are well supported by spectroscopic data. From the enzyme inhibition data (Table-1 & 2), it was obvious that the compounds possessed moderate to talented activity against acetylcholinesterase, butyrylcholinesterase and lipoxygenase enzymes which was evident from their IC₅₀ values, relative to the standard used. All compounds showed good scavenging activity against DPPH but all *N*-ethyl substituted sulfonamides stayed inactive. Hence, on the basis of aforesaid results, it was generally concluded that the derivatives without *N*-ethyl substitution seem relatively more suitable drug candidates for the treatment of Alzheimer's disease and other associated diseases. These entrants can also be helpful for the treatment of a variety of disorders such as bronchial asthma, inflammation, cancer and autoimmune diseases.

ACKNOWLEDGMENT

The authors are thankful to Higher Education Commission of Pakistan for financial support.

REFERENCES

1. F. Sanchez-Sancho, B. Herrandón. Short syntheses of (S)-pipecolic acid, (R)-coniine, and (S)-coniceine using biocatalytically-generated chiral building block. *Tetrahedron: Asymmetry*. 1998; 9: 1951-1965.
2. S. Nithiya, N. Karthik, J. Jayabharathi. *In vitro* antioxidant activity of hindered piperidone derivatives. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2011; 3(3): 254-256.
3. B. Adger, U. Dyer, G. Hutton, M. Woods. Stereospecific Synthesis of the Anaesthetic Levobupivacaine. *Tetrahedron Letter*. 1996; 37: 6399-6402.
4. D.I.C. Scopes, N.F. Hayes, D.F. Bays, D. Belton, J. Brain, D.S. Brown, D.B. Judd, A.B. McElroy, C.A. Meerholz, A. Naylos, A.G. Hayes, M.J. Sheehan, P.J. Birch, M.B. J. Tyers. New kappa-receptor agonists based upon a 2-[(alkylamino)methyl] piperidine nucleus. *Journal of Medicinal Chemistry*. 1992; 35: 490-501.
5. J.W. Daly, T.F. Spande. *Alkaloids: Chemical and Biological Perspectives*, S. W. Pelletier, Ed; Wiley: New York. 1986; 4: 1-254.
6. G.B. Fodor, B. Colasanti. *Alkaloids: Chemical and Biological Perspectives*, S. W. Pelletier, Ed; Wiley: New York. 1985; 3: 1-91.
7. L.A. Campfield, F.J. Smith, G. Mackie, R. Tenenbaum, M.L. Sassano, J. Mullin, R.W. Kierstead. Insulin normalization as an approach to

the pharmacological treatment of obesity. *Obesity Research & Clinical Practice*. 1995; 3: 591S-603S.

8. A.P. Kozikowski, G. L. Araldi, J. Boja, W.M. Meil, K.M. Johnson, J.L. Flippen. Chemistry and Pharmacology of the Piperidine-Based Analogues of Cocaine Identification of Potent DAT Inhibitors Lacking the Tropane Skeleton. *Journal of Medicinal Chemistry*. 1998; 41: 1962-1969.
9. M.E. Brau, P. Branitzki, A. Olschewski, W. Vogeland, G. Hempelmann. Block of neuronal tetrodotoxin-resistant Na⁺ currents by stereoisomers of piperidine local anesthetics. *Anesthesia & Analgesia*. 2000; 91: 1499-1505.
10. V.da.S. Bolzani, A.A.L. Gunatilaka, D. G. I. Kingston. Bioactive and Other Piperidine Alkaloids from *Cassia leptophylla*. *Tetrahedron*. 1995; 51: 5929-5934.
11. C.T. Supuran, A. Casini, A. Scozzafava. Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. *Medicinal Research Reviews*. 2003; 23: 535-558.
12. C.T. Supuran, A. Innocenti, A. Mastrolorenzo, A. Scozzafava. Antiviral sulfonamide derivatives. *Mini-Rev. Journal of Medicinal Chemistry*. 2004; 4: 189-200.
13. G.A. Cordell. *The Alkaloids Chemistry and Biology*. Academic Press; San Diego. 2000; 5.
14. M. Cygler, J.D. Schrag, J. Sussman, L.M. Harel, I. Silman, M.K. Gentry. Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases and related proteins. *Protein Science*. 1993; 2: 366-382.
15. V. Tougu. Acetylcholinesterase: Mechanism of Catalysis and Inhibition. *Current Medicinal Chemistry*. 2001; 1: 155-170.
16. S. Gauthier. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease. *Drug Aging*. 2001; 18: 853-862.
17. G. Bertaccini, *Handbook of Experimental Pharmacology*. Springer, Berlin. 1982; 59/II: 85-10.
18. G.L. Ellman, K.D. Courtney, V. Andres, R.M. Featherstone. A new and rapid calorimetric determination of acetylcholinesterase activity. *Biochemical Pharmacology*. 1961; 7: 88-95.
19. A.L. Tappel. The mechanism of the oxidation of unsaturated fatty acid catalyzed by hematin compounds. *Archives of Biochemistry and Biophysics*. 1953; 44(2): 378-395.
20. A.T. Evans. Actions of cannabis constituents on enzymes of arachidonate metabolism: anti-inflammatory potential. *Biochemical Pharmacology*. 1987; 36: 2035-2037.
21. S. Baylac, P. Racine. Inhibition of 5-lipoxygenase by essential oils and other natural fragrant extracts. *International Journal of Aromatherapy*. 2003; 13: 138-142.

22. D.J. Huang, H.J. Chen, C.D. Lin, Y.H. Lin. Antioxidant and antiproliferative activities of water spinach (*Ipomoea aquatic* Forsk) constituents. *Botanical Bulletin of Academia Sinica*.2005; 46: 99-106.
23. X. Deng, N.S. Mani. A facile, environmentally benign sulfonamide synthesis in water. *Green Chemistry*. 2006; 8: 835-838.
24. M. Jafarpour, A. Rezaeifard, T. Golshani. A Green, Catalyst-Free Method for the Synthesis of Sulfonamides and Sulfonylazides. *Journal of Phosphorous, Sulfur, and Silicon*. 2011; 186: 140-148.